240 related articles for article (PubMed ID: 21521770)
1. Substrate specificity and ligand interactions of CYP26A1, the human liver retinoic acid hydroxylase.
Thatcher JE; Buttrick B; Shaffer SA; Shimshoni JA; Goodlett DR; Nelson WL; Isoherranen N
Mol Pharmacol; 2011 Aug; 80(2):228-39. PubMed ID: 21521770
[TBL] [Abstract][Full Text] [Related]
2. Induction of CYP26A1 by metabolites of retinoic acid: evidence that CYP26A1 is an important enzyme in the elimination of active retinoids.
Topletz AR; Tripathy S; Foti RS; Shimshoni JA; Nelson WL; Isoherranen N
Mol Pharmacol; 2015; 87(3):430-41. PubMed ID: 25492813
[TBL] [Abstract][Full Text] [Related]
3. Regulation of a highly specific retinoic acid-4-hydroxylase (CYP26A1) enzyme and all-trans-retinoic acid metabolism in human intestinal, liver, endothelial, and acute promyelocytic leukemia cells.
Ozpolat B; Mehta K; Lopez-Berestein G
Leuk Lymphoma; 2005 Oct; 46(10):1497-506. PubMed ID: 16194896
[TBL] [Abstract][Full Text] [Related]
4. Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver Retinoic Acid Hydroxylase.
Diaz P; Huang W; Keyari CM; Buttrick B; Price L; Guilloteau N; Tripathy S; Sperandio VG; Fronczek FR; Astruc-Diaz F; Isoherranen N
J Med Chem; 2016 Mar; 59(6):2579-95. PubMed ID: 26918322
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the function and expression of CYP26A1 and CYP26B1, the two retinoic acid hydroxylases.
Topletz AR; Thatcher JE; Zelter A; Lutz JD; Tay S; Nelson WL; Isoherranen N
Biochem Pharmacol; 2012 Jan; 83(1):149-63. PubMed ID: 22020119
[TBL] [Abstract][Full Text] [Related]
6. Molecular recognition of CYP26A1 binding pockets and structure-activity relationship studies for design of potent and selective retinoic acid metabolism blocking agents.
Sun B; Song S; Hao CZ; Huang WX; Liu CC; Xie HL; Lin B; Cheng MS; Zhao DM
J Mol Graph Model; 2015 Mar; 56():10-9. PubMed ID: 25541526
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the roles of peroxisome proliferator-activated receptor and retinoic acid receptor on CYP26 regulation.
Tay S; Dickmann L; Dixit V; Isoherranen N
Mol Pharmacol; 2010 Feb; 77(2):218-27. PubMed ID: 19884280
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.
Sun B; Liu K; Han J; Zhao LY; Su X; Lin B; Zhao DM; Cheng MS
Bioorg Med Chem; 2015 Oct; 23(20):6763-73. PubMed ID: 26365710
[TBL] [Abstract][Full Text] [Related]
9. A novel human cytochrome P450, CYP26C1, involved in metabolism of 9-cis and all-trans isomers of retinoic acid.
Taimi M; Helvig C; Wisniewski J; Ramshaw H; White J; Amad M; Korczak B; Petkovich M
J Biol Chem; 2004 Jan; 279(1):77-85. PubMed ID: 14532297
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26).
Gomaa MS; Bridgens CE; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
J Med Chem; 2011 Oct; 54(19):6803-11. PubMed ID: 21838328
[TBL] [Abstract][Full Text] [Related]
11. Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold.
Gomaa MS; Bridgens CE; Illingworth NA; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
Bioorg Med Chem; 2012 Jul; 20(14):4201-7. PubMed ID: 22727372
[TBL] [Abstract][Full Text] [Related]
12. CRABPs Alter
Yabut KCB; Isoherranen N
Nutrients; 2022 Apr; 14(9):. PubMed ID: 35565751
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective formation and metabolism of 4-hydroxy-retinoic Acid enantiomers by cytochrome p450 enzymes.
Shimshoni JA; Roberts AG; Scian M; Topletz AR; Blankert SA; Halpert JR; Nelson WL; Isoherranen N
J Biol Chem; 2012 Dec; 287(50):42223-32. PubMed ID: 23071109
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates.
Gomaa MS; Lim AS; Lau SC; Watts AM; Illingworth NA; Bridgens CE; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
Bioorg Med Chem; 2012 Oct; 20(20):6080-8. PubMed ID: 22989911
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the
Stevison F; Hogarth C; Tripathy S; Kent T; Isoherranen N
Drug Metab Dispos; 2017 Jul; 45(7):846-854. PubMed ID: 28446509
[No Abstract] [Full Text] [Related]
16. Regulation of CYP26A1 expression by selective RAR and RXR agonists in human NB4 promyelocytic leukemia cells.
Idres N; Marill J; Chabot GG
Biochem Pharmacol; 2005 Jun; 69(11):1595-601. PubMed ID: 15896339
[TBL] [Abstract][Full Text] [Related]
17. Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase.
Lutz JD; Dixit V; Yeung CK; Dickmann LJ; Zelter A; Thatcher JE; Nelson WL; Isoherranen N
Biochem Pharmacol; 2009 Jan; 77(2):258-68. PubMed ID: 18992717
[TBL] [Abstract][Full Text] [Related]
18. Functional properties and substrate characterization of human CYP26A1, CYP26B1, and CYP26C1 expressed by recombinant baculovirus in insect cells.
Helvig C; Taimi M; Cameron D; Jones G; Petkovich M
J Pharmacol Toxicol Methods; 2011; 64(3):258-63. PubMed ID: 21906690
[TBL] [Abstract][Full Text] [Related]
19. Novel tetralone-derived retinoic acid metabolism blocking agents: synthesis and in vitro evaluation with liver microsomal and MCF-7 CYP26A1 cell assays.
Yee SW; Jarno L; Gomaa MS; Elford C; Ooi LL; Coogan MP; McClelland R; Nicholson RI; Evans BA; Brancale A; Simons C
J Med Chem; 2005 Nov; 48(23):7123-31. PubMed ID: 16279770
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of substituted imidazole and triazole N-phenylbenzo[d]oxazolamine inhibitors of retinoic acid metabolizing enzyme CYP26.
Pautus S; Aboraia AS; Bassett CE; Brancale A; Coogan MP; Simons C
J Enzyme Inhib Med Chem; 2009 Apr; 24(2):487-98. PubMed ID: 18608743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
